Acadia Pharmaceuticals ACAD Other liabilities
Other liabilities at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Acadia Pharmaceuticals's other liabilities?
- Acadia Pharmaceuticals (ACAD) reported other liabilities of -$6.5M in Q1 2026.
- How has Acadia Pharmaceuticals's other liabilities changed year-over-year?
- Acadia Pharmaceuticals's other liabilities decreased by 440.8% year-over-year, from $1.91M to -$6.5M.
- What is the long-term trend for Acadia Pharmaceuticals's other liabilities?
- Over 3 years (2021 to 2025), Acadia Pharmaceuticals's other liabilities has grown at a -16.5% compound annual growth rate (CAGR), from $1.85M to $1.08M.